Clinical Trial Update: Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant chemoimmunotherapy trial for resectable head and neck squamous cell carcinoma using camrelizumab with paclitaxel and carboplatin; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Laryngeal Cancer
• Oral Cavity Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Camrelizumab (camrelizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia | Conditions: Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING